[Reversion of multidrug resistance in vitro of lung adenocarcinoma by mdr1 ribozyme]

Zhonghua Zhong Liu Za Zhi. 2000 May;22(3):189-91.
[Article in Chinese]

Abstract

Objective: To investigate the possibility of reversion of multidrug resistant (MDR) in lung adenocarcinoma-resistant cell line A549/R by mdr1 ribozyme.

Methods: With GUC at 880 site of mdr1 mRNA selected as target point, plasmid expressing mdr1 ribozyme (pH beta Apr-1 neo/mdr1-Rb) was transduced to A549/R by lipofectin. The expression of mdr1 mRNA and Pgp, cellular rhodamine accumulation and sensitivity to doxorubicin were examined in ribozyme transduced and non-transduced cells.

Results: Transduction of mdr1 ribozyme to A549/R cells led to decrease in mdr1 mRNA and Pgp expression; increase in rhodamine accumulation. The sensitivity of the ribozyme transduced cells to doxorubicin was 200-fold as high as that of the parental drug-resistant cells.

Conclusion: MDR of lung adenocarcinoma-resistant cell line A549/R can be effectively reversed with mdr1 ribozyme by cleavage of mdr1 mRNA and inhibition of Pgp expression.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / biosynthesis
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
  • Adenocarcinoma
  • Antineoplastic Agents / pharmacology*
  • Cell Division / drug effects
  • Doxorubicin / pharmacology
  • Drug Resistance, Multiple / physiology*
  • Drug Synergism
  • Humans
  • Lung Neoplasms
  • RNA, Catalytic / pharmacology*
  • RNA, Messenger / drug effects
  • RNA, Messenger / metabolism
  • Tumor Cells, Cultured

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antineoplastic Agents
  • RNA, Catalytic
  • RNA, Messenger
  • Doxorubicin